605116.SH
奥锐特
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 19.48
−2.36%Aug 28, 2026, 08:42 UTC
Aoruite announced its first-half 2026 results: net profit attributable to shareholders was 159 million yuan, down 32.42% year-on-year.
Source:Aug 24, 2026, 09:22 UTC
Aurit's wholly-owned subsidiary Yangzhou Aurit received a drug supplementary application approval notice from China's National Medical Products Administration for a new 1mg specification of estradiol tablets/estradiol-dydrogesterone tablets composite packaging.
Source:Jul 15, 2026, 09:11 UTC
China's National Health Commission and two other departments added Aurisco's main drug dydrogesterone tablets to the 2026 edition of the National Essential Drugs List, effective September 1, 2026.
Source:Jul 13, 2026, 07:34 UTC
Aurita's eplerenone API production line passed GMP compliance inspection by Zhejiang Medical Products Administration.
Source: